ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
4 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
302
|
219K
|
4
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
11 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
302
|
219K
|
11
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
2 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
302
|
219K
|
2
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
3 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
302
|
219K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Blockbuster
|
40 |
18K |
11 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
40
|
18K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Blockbuster
|
40 |
18K |
8 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
40
|
18K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Sarepta eyes multiple sclerosis gene therapy
|
|
Blockbuster
|
40 |
18K |
19 |
12/08/19 |
12/08/19 |
ASX - By Stock
|
40
|
18K
|
19
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
3 |
09/08/19 |
09/08/19 |
ASX - By Stock
|
302
|
219K
|
3
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
6 |
09/08/19 |
09/08/19 |
ASX - By Stock
|
302
|
219K
|
6
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
7 |
09/08/19 |
09/08/19 |
ASX - By Stock
|
302
|
219K
|
7
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
6 |
08/08/19 |
08/08/19 |
ASX - By Stock
|
302
|
219K
|
6
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
4 |
08/08/19 |
08/08/19 |
ASX - By Stock
|
302
|
219K
|
4
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
6 |
08/08/19 |
08/08/19 |
ASX - By Stock
|
302
|
219K
|
6
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
13 |
08/08/19 |
08/08/19 |
ASX - By Stock
|
302
|
219K
|
13
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
5 |
07/08/19 |
07/08/19 |
ASX - By Stock
|
302
|
219K
|
5
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
4 |
06/08/19 |
06/08/19 |
ASX - By Stock
|
302
|
219K
|
4
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
4 |
06/08/19 |
06/08/19 |
ASX - By Stock
|
302
|
219K
|
4
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
3 |
06/08/19 |
06/08/19 |
ASX - By Stock
|
302
|
219K
|
3
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
11 |
06/08/19 |
06/08/19 |
ASX - By Stock
|
302
|
219K
|
11
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
1 |
05/08/19 |
05/08/19 |
ASX - By Stock
|
302
|
219K
|
1
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
6 |
05/08/19 |
05/08/19 |
ASX - By Stock
|
302
|
219K
|
6
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
5 |
05/08/19 |
05/08/19 |
ASX - By Stock
|
302
|
219K
|
5
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
2 |
05/08/19 |
05/08/19 |
ASX - By Stock
|
302
|
219K
|
2
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
6 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
6
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
5 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
5
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
3 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
3
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
0 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
0
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
2 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
2
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
1 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
1
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
5 |
30/07/19 |
30/07/19 |
ASX - By Stock
|
302
|
219K
|
5
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
5 |
29/07/19 |
29/07/19 |
ASX - By Stock
|
302
|
219K
|
5
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
10 |
29/07/19 |
29/07/19 |
ASX - By Stock
|
302
|
219K
|
10
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
3 |
28/07/19 |
28/07/19 |
ASX - By Stock
|
302
|
219K
|
3
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
2 |
28/07/19 |
28/07/19 |
ASX - By Stock
|
302
|
219K
|
2
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
7 |
28/07/19 |
28/07/19 |
ASX - By Stock
|
302
|
219K
|
7
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
12 |
26/07/19 |
26/07/19 |
ASX - By Stock
|
302
|
219K
|
12
|
|
ASX - By Stock
|
PER |
Re:
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
21 |
26/07/19 |
26/07/19 |
ASX - By Stock
|
302
|
219K
|
21
|
|
ASX - By Stock
|
PER |
DMD Phase 2 Results in Q4 = Potential 5000% Gem
|
|
Blockbuster
|
302 |
219K |
22 |
26/07/19 |
26/07/19 |
ASX - By Stock
|
302
|
219K
|
22
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
0 |
15/01/19 |
15/01/19 |
ASX - By Stock
|
28
|
9.5K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
4 |
15/01/19 |
15/01/19 |
ASX - By Stock
|
28
|
9.5K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
5 |
15/01/19 |
15/01/19 |
ASX - By Stock
|
28
|
9.5K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
1 |
14/01/19 |
14/01/19 |
ASX - By Stock
|
28
|
9.5K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
0 |
14/01/19 |
14/01/19 |
ASX - By Stock
|
28
|
9.5K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
5 |
14/01/19 |
14/01/19 |
ASX - By Stock
|
28
|
9.5K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
10 |
03/01/19 |
03/01/19 |
ASX - By Stock
|
28
|
9.5K
|
10
|
|
ASX - By Stock
|
RAC |
Mcap $6.7 M / Big EFFECTIVE Cancer Drug in P3 (MKT Size ~$500M+) =20+BAGGER
|
|
Blockbuster
|
28 |
9.5K |
7 |
03/01/19 |
03/01/19 |
ASX - By Stock
|
28
|
9.5K
|
7
|
|
ASX - By Stock
|
RAC |
5 Million Shares bought by Insider
|
|
Blockbuster
|
21 |
10K |
8 |
02/01/19 |
02/01/19 |
ASX - By Stock
|
21
|
10K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
2019 SP
|
|
Blockbuster
|
116 |
47K |
7 |
02/01/19 |
02/01/19 |
ASX - By Stock
|
116
|
47K
|
7
|
|
ASX - By Stock
|
RAC |
Re:
News: RAC Race Oncology Announces Agreement With Truemed For Bisantrene NPP In Israel
|
|
Blockbuster
|
12 |
4.4K |
2 |
31/12/18 |
31/12/18 |
ASX - By Stock
|
12
|
4.4K
|
2
|
|
ASX - By Stock
|
IMC |
If Partner Deal then expect $40+ M upfront payment
|
|
Blockbuster
|
4 |
3.7K |
0 |
24/03/17 |
24/03/17 |
ASX - By Stock
|
4
|
3.7K
|
0
|
|